QNB CORP.·4

Feb 18, 3:23 PM ET

Orzehoski Scott G 4

4 · QNB CORP. · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

QNB CORP (QNBC) EVP Scott Orzehoski Receives Restricted Stock Award

What Happened
Scott G. Orzehoski, EVP & Chief Lending Officer of QNB CORP. (QNBC), was granted a total of 1,500 shares as an award on February 13, 2026. The grant is reported as acquisition code "A" (award/grant): 750 shares acquired outright at $38.00 each ($28,500) and three derivative awards of 250 shares each at $38.00 ($9,500 each), for a combined value of approximately $57,000. Footnote F1 identifies these as Restricted Stock Awards.

Key Details

  • Transaction date: 2026-02-13; Filing date (Form 4): 2026-02-18.
  • Reported per-share price: $38.00.
  • Breakdown: 750 shares (Acquired) + 250 + 250 + 250 (three derivative acquisitions) = 1,500 total shares; total value ≈ $57,000.
  • Footnote F1: Restricted Stock Award.
  • Shares owned after transaction: Not stated in this filing.
  • Timeliness: Filed Feb 18; given the Feb 13 transaction and the Presidents Day holiday (Feb 16), the Form 4 appears to have been filed one business day after the two-business-day reporting deadline.

Context
These entries are awards (compensation) rather than open-market purchases or sales. Restricted stock awards are typically subject to vesting and other restrictions and do not necessarily indicate immediate market buying or selling by the insider. The three entries labeled as derivative transactions reflect award reporting details, not option exercises or sales.

Insider Transaction Report

Form 4
Period: 2026-02-13
Orzehoski Scott G
EVP Chief Lending Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-02-13$38.00/sh+750$28,50016,842.881 total
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2026-02-13Exp: 2036-02-13Common Stock (250 underlying)
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2027-02-13Exp: 2036-02-13Common Stock (250 underlying)
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2028-02-13Exp: 2036-02-13Common Stock (250 underlying)
Holdings
  • Common Stock(Right to Buy)

    Exercise: $37.26From: 2025-02-15Exp: 2027-02-15Common Stock (3,500 underlying)
    3,500
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2024-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2025-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2026-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2027-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2028-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2025-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2026-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2027-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2028-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2029-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2026-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2027-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2028-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2029-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2030-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
Footnotes (1)
  • [F1]Restricted Stock Award
Signature
Scott Orzehoski|2026-02-18

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT